**Supplementary Table 1: Members of the HTAi Policy Forum, HTAi Policy Forum Committee, HTAi Board, HTAi Secretariat, Forum observers and invited speakers for the 29th – 31st January 2017 HTAi Global Policy Forum meeting, Barcelona, Spain.**

|  |  |
| --- | --- |
| **Meeting Participants** | |
| **Name** | **Organization** |
| Jeonghoon Ahn | Ewha Womans University, South Korea |
| Wendy Babidge | Royal Australasian College of Surgeons |
| Suzanne Belinson | Blue Cross Blue Shield Association (BCBSA), USA |
| Chantal Bélorgey | French National Authority for Health (HAS) |
| Meindert Boysen | National Institute for Health and Care Excellence (NICE), England |
| Andrew Bruce | AMGEN, Inc. |
| Lars Brüning | Bayer Pharma AG |
| Agnès Buzyn | French National Authority for Health (HAS) |
| Barbara Calvert | Abbott |
| Yingyao Chen | Fudan University, China |
| Americo Cicchetti | Università Cattolica del Sacro Cuore, Italy |
| Alexandra Clyde | Medtronic |
| Elizabeth Cobbs | Merck & Co., Inc. |
| Joe Cook | Pfizer Inc |
| Nigel Cook | Novartis Pharma AG |
| Nick Crabb | National Institute for Health and Care Excellence (NICE), England |
| Sophie Cros | Abbott |
| Frederique deBroucker | Medtronic |
| Diana Delnoij | National Healthcare Institute (ZIN), The Netherlands |
| Signe Flottorp | Norwegian Institute of Public Health |
| Brent Fraser | Canadian Agency for Drugs and Technologies (CADTH) |
| Brynjar Fure | Norwegian Institute of Public Health |
| Lou Garrison | University of Washington, USA |
| John Graham | GlaxoSmithKline |
| David Grainger | Eli Lilly and Company |
| Alicia Granados | Sanofi Genzyme |
| Adrian Griffin | Johnson & Johnson |
| Jens Grueger | F. Hoffman-La Roche AG |
| Fay Habens | Wessex Institute Enterprise and Partnerships, University of Southampton, England |
| Ansgar Hebborn | F. Hoffman-La Roche AG |
| Niklas Hedberg | Dental and Pharmaceuticals Benefits Agency (TLV), Sweden |
| Keiji Iwashita | Takeda Pharmaceuticals International |
| Don Juzwishin | Alberta Health Services, Canada |
| Brendon Kearney | Health Policy Advisory Committee on Technology, Australia |
| Seok Hyun Kim | National Evidence-based Healthcare Collaborating Agency (NECA), South Korea |
| Dell Kingsford Smith | Janssen Global Services, LLC |
| Herve Lamarque | Bristol-Myers Squibb |
| Krzysztof Łanda | Ministry of Health, Poland |
| Jake Lebiecki | Pfizer |
| Young Sung Lee | National Evidence-based Healthcare Collaborating Agency (NECA), South Korea |
| Philippe Legenne | AMGEN, Inc. |
| Gavin Lewis | AstraZeneca |
| Jan Liliemark | Swedish Council on Health Technology Assessment (SBU) |
| Carole Longson | National Institute for Health and Care Excellence (NICE), England |
| Guy Maddern | University of Adelaide, Australia |
| Ramneek Mahal | GlaxoSmithKline |
| Mark McIntyre | Boston Scientific |
| Jo Merritt | Wessex Institute Enterprise and Partnerships, University of Southampton, England |
| François Meyer | French National Authority for Health (HAS) |
| Simona Montilla | Italian Medicines Agency (AIFA) |
| John O'Donnell | Bristol-Myers Squibb |
| Dan Ollendorf | Institute for Clinical and Economic Review (ICER), USA |
| Wija Oortwijn | Ecorys, The Netherlands |
| Brian O'Rourke | Canadian Agency for Drugs and Technologies (CADTH) |
| Parashar Patel | Boston Scientific |
| Steve Pearson | Institute for Clinical and Economic Review (ICER), USA |
| Gesa Pellier | Novartis Pharma AG |
| Milena Richter | Sanofi |
| Alric Rüther | Institute for Quality and Efficiency in Health Care (IQWiG), Germany |
| Bettina Ryll | Melanoma Patient Network Europe, Sweden |
| Laura Sampietro-Colom | Hospital Clinic Barcelona, Spain |
| Lars Sandman | Linköping University, Sweden |
| Susan Shiff | Merck & Co., Inc. |
| Jean Slutsky | Patient-Centered Outcomes Research Institute (PCORI), USA |
| Louise Timlin | Eli Lilly and Company |
| Sean Tunis | Centre for Medical Technology Policy (CMTP), USA |
| Lucy Turner | Health Technology Assessment international (HTAi) |
| Jocelyn Ulrich | Merck Serono |
| Sophie Söderholm Werko | Swedish Agency for Health Technology Assessment (SBU) |
| Kaoru Yamabe | Takeda Pharmaceuticals International |
| **HTAi Policy Forum Committee** | |
| **Name** | **Role and Organization** |
| Laura Sampietro-Colom | HTAi Policy Forum Chair, Hospital Clinic Barcelona, Spain |
| Barbara Calvert | HTAi Policy Forum Committee member, Abbott |
| Tammy Clifford | HTAi Policy Forum Committee member, Canadian Agency for Drugs and Technologies (CADTH) |
| Elizabeth Cobbs | HTAi Policy Forum Committee member, Merck & Co., Inc. |
| Joseph Cook | HTAi Policy Forum Committee member, Pfizer |
| Wim Goettsch | HTAi Policy Forum Committee member, National Healthcare Institute (ZIN), The Netherlands |
| Guy Maddern | HTAi Policy Forum Committee member, University of Adelaide, Australia |
| Wija Oortwijn | HTAi Policy Forum Scientific Secretary (2016-17), Ecorys, The Netherlands |
| Sean Tunis | HTAi Policy Forum Committee member, Centre for Medical Technology Policy (CMTP), USA |